论文部分内容阅读
作者对难治性转移癌病人进行了 rhGM-CSF 不同应用方法的临床研究,以确定 rhGM-CSF 对血液系统的影响和副作用。病人和方法男7、女3例,年龄39～70(平均59)岁,均为对常规治疗无效的转移癌病人,且至少8周内未接受放疗或化疗。病种包括肺腺癌3例、晚期结直肠癌3例和乳腺癌、子宫内膜癌、鼻咽癌、绒毛膜胚胎癌各1例。病人分为两组,每组5例。首先,小剂量组和大剂量组分别给予5μg/M~2和25μg/M~2 rhGM-CSF 快速静脉推注,观察注射后的急性反应;6天后,分别每日给予100μg/M~2和500μg/M~2rhGM-CSF 静脉滴注,连续14天。研究期间不服用糖皮质激素.结果和讨论静脉推注 rhGM-CSF 后5～
The authors conducted a clinical study of various applications of rhGM-CSF in patients with refractory metastatic disease to determine the effects and side effects of rhGM-CSF on the blood system. Patients and Methods Male 7 and female 3 patients, aged 39-70 (mean 59 years), were all metastatic cancer patients who were ineffective in conventional therapy and had not received radiotherapy or chemotherapy for at least 8 weeks. Diseases including 3 cases of lung adenocarcinoma, 3 cases of advanced colorectal cancer and breast cancer, endometrial cancer, nasopharyngeal carcinoma, choriocarcinoma in 1 case. The patients were divided into two groups of 5 patients each. First, the small dose group and high dose group were given 5μg / M ~ 2 and 25μg / M ~ 2 rhGM-CSF rapid intravenous injection to observe the acute response after injection; 6 days later, were given daily 100μg / M ~ 2 and 500μg / M ~ 2rhGM-CSF intravenous infusion for 14 days. During the study did not take glucocorticoid.Results and discussion After intravenous injection of rhGM-CSF 5 ~